Intermediatebiotechnology
Genetic Disorders Overview
Overview
Genetic disorders arise from DNA abnormalities: single-gene (Mendelian: CF, Huntington's, sickle cell), chromosomal (Down syndrome, Turner), and multifactorial (heart disease, diabetes: genes + environment). ~7,000 rare Mendelian disorders affect ~300 million people collectively; multifactorial diseases dominate mortality. Diagnosis, counseling, and emerging therapies (gene therapy, CRISPR) define modern management.
Learning objectives
- Classify disorder types
- Estimate burden and frequency
- Explain diagnosis pathways
- Survey treatment approaches
Single-gene disorders
~7,000 known; individually rare, collectively common (~1 in 17 people affected by a rare disease). Autosomal dominant (Huntington's), recessive (CF, Tay-Sachs), X-linked (hemophilia, DMD). Most are serious, early-onset, and lack cures: management is symptomatic plus surveillance.
~300 million people worldwide live with a rare disease: not rare at all.
Chromosomal disorders
Aneuploidies (Down 1/700, Edwards, Patau), deletions/duplications (cri-du-chat, 22q11.2), sex chromosome (Turner, Klinefelter). Usually de novo (nondisjunction) with low recurrence; maternal age raises trisomy risk. Microarray is first-line diagnosis for developmental delay.
Most chromosomal disorders are new mutations: parents' recurrence risk is low (~1%).
Multifactorial disorders
Heart disease, diabetes, schizophrenia, most cancers: many variants (polygenic risk) plus environment. Heritability is substantial but no single gene explains cases; GWAS/PRS stratify risk. Prevention targets modifiable factors; genetics guides screening intensity.
No single 'diabetes gene': risk is distributed across thousands of variants.
Management and hope
Symptomatic care, surveillance protocols, genetic counseling, prenatal options; emerging: enzyme replacement, small molecules (CFTR modulators: Trikafta), gene therapy (Luxturna, Zolgensma), CRISPR (Casgevy). Diagnosis itself is therapeutic: ending the diagnostic odyssey.
You cannot treat what you cannot name: genomic diagnosis unlocks everything downstream.
Key points
- Single-gene (~7,000 rare), chromosomal (de novo aneuploidies), multifactorial (common diseases)
- Rare diseases collectively affect ~1 in 17
- Chromosomal usually de novo; Mendelian follow pedigree risks
- Therapies: symptomatic, modulators, gene therapy, CRISPR
Common misconceptions
✓ Truth: CFTR modulators, enzyme replacement, gene therapies, and even dietary (PKU) treatments prove otherwise.
✓ Truth: Recessive carriers are healthy; de novo cases don't affect siblings; penetrance varies.
Practice questions
Q1. Which class dominates human mortality?
- Single-gene
- Chromosomal
- Multifactorial (heart disease, diabetes, cancer)
- Mitochondrial
Common multifactorial diseases cause most deaths, though each has genetic components.
Q2. Most chromosomal disorders are
- Inherited from parents
- De novo with low recurrence risk
- Contagious
- Preventable by diet
Nondisjunction usually occurs sporadically: recurrence ~1%.
Q3. Trikafta treats cystic fibrosis by
- Gene editing
- Modulating mutant CFTR protein function
- Lung transplant
- Antibiotics only
Small-molecule correctors/potentiators restore CFTR activity.
Click a question to reveal the answer and explanation.
Frequently asked questions
What is the diagnostic odyssey?
Years of inconclusive tests rare-disease patients endure; exome sequencing now ends many odysseys.
How do CFTR modulators work?
Small molecules (ivacaftor/lumacaftor/tezacaftor/elexacaftor) correct folding/gating of mutant CFTR: function restored pharmacologically.
Why screen newborns?
Conditions like PKU are treatable only if caught before damage: screening enables pre-symptomatic intervention.